![]() |
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Fusion gene ID: 24269 |
FusionGeneSummary for NFKB1_NFKB1 |
![]() |
Fusion gene information | Fusion gene name: NFKB1_NFKB1 | Fusion gene ID: 24269 | Hgene | Tgene | Gene symbol | NFKB1 | NFKB1 | Gene ID | 4790 | 4790 |
Gene name | nuclear factor kappa B subunit 1 | nuclear factor kappa B subunit 1 | |
Synonyms | CVID12|EBP-1|KBF1|NF-kB1|NF-kappa-B|NF-kappaB|NFKB-p105|NFKB-p50|NFkappaB|p105|p50 | CVID12|EBP-1|KBF1|NF-kB1|NF-kappa-B|NF-kappaB|NFKB-p105|NFKB-p50|NFkappaB|p105|p50 | |
Cytomap | 4q24 | 4q24 | |
Type of gene | protein-coding | protein-coding | |
Description | nuclear factor NF-kappa-B p105 subunitDNA-binding factor KBF1NF-kappabetanuclear factor NF-kappa-B p50 subunitnuclear factor kappa-B DNA binding subunitnuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | nuclear factor NF-kappa-B p105 subunitDNA-binding factor KBF1NF-kappabetanuclear factor NF-kappa-B p50 subunitnuclear factor kappa-B DNA binding subunitnuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | |
Modification date | 20180527 | 20180527 | |
UniProtAcc | P19838 | P19838 | |
Ensembl transtripts involved in fusion gene | ENST00000226574, ENST00000394820, ENST00000505458, ENST00000510638, ENST00000600343, | ENST00000226574, ENST00000394820, ENST00000505458, ENST00000510638, ENST00000600343, | |
Fusion gene scores | * DoF score | 5 X 5 X 4=100 | 2 X 2 X 2=8 |
# samples | 6 | 3 | |
** MAII score | log2(6/100*10)=-0.736965594166206 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/8*10)=1.90689059560852 | |
Context | PubMed: NFKB1 [Title/Abstract] AND NFKB1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | NFKB1 | GO:0010629 | negative regulation of gene expression | 26687115 |
Hgene | NFKB1 | GO:0010956 | negative regulation of calcidiol 1-monooxygenase activity | 15243130 |
Hgene | NFKB1 | GO:0045893 | positive regulation of transcription, DNA-templated | 17426251 |
Hgene | NFKB1 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 1406630 |
Hgene | NFKB1 | GO:1900127 | positive regulation of hyaluronan biosynthetic process | 17324121 |
Tgene | NFKB1 | GO:0010629 | negative regulation of gene expression | 26687115 |
Tgene | NFKB1 | GO:0010956 | negative regulation of calcidiol 1-monooxygenase activity | 15243130 |
Tgene | NFKB1 | GO:0045893 | positive regulation of transcription, DNA-templated | 17426251 |
Tgene | NFKB1 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 1406630 |
Tgene | NFKB1 | GO:1900127 | positive regulation of hyaluronan biosynthetic process | 17324121 |
![]() (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChiTaRS3.1 | CA311701 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + | ||
ChiTaRS3.1 | CA313276 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
3UTR-3UTR | ENST00000226574 | ENST00000226574 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000226574 | ENST00000394820 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000226574 | ENST00000505458 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-intron | ENST00000226574 | ENST00000510638 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000226574 | ENST00000600343 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-3UTR | ENST00000394820 | ENST00000226574 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-3UTR | ENST00000394820 | ENST00000394820 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-3UTR | ENST00000394820 | ENST00000505458 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-intron | ENST00000394820 | ENST00000510638 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-3UTR | ENST00000394820 | ENST00000600343 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000505458 | ENST00000226574 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000505458 | ENST00000394820 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000505458 | ENST00000505458 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-intron | ENST00000505458 | ENST00000510638 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000505458 | ENST00000600343 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-3UTR | ENST00000510638 | ENST00000226574 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-3UTR | ENST00000510638 | ENST00000394820 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-3UTR | ENST00000510638 | ENST00000505458 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-intron | ENST00000510638 | ENST00000510638 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
intron-3UTR | ENST00000510638 | ENST00000600343 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000600343 | ENST00000226574 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000600343 | ENST00000394820 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000600343 | ENST00000505458 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-intron | ENST00000600343 | ENST00000510638 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
3UTR-3UTR | ENST00000600343 | ENST00000600343 | NFKB1 | chr4 | 103538082 | - | NFKB1 | chr4 | 103537757 | + |
Top |
FusionProtFeatures for NFKB1_NFKB1 |
![]() |
Hgene | Tgene |
NFKB1 | NFKB1 |
NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}. | NF-kappa-B is a pleiotropic transcription factor presentin almost all cell types and is the endpoint of a series of signaltransduction events that are initiated by a vast array of stimulirelated to many biological processes such as inflammation,immunity, differentiation, cell growth, tumorigenesis andapoptosis. NF-kappa-B is a homo- or heterodimeric complex formedby the Rel-like domain-containing proteins RELA/p65, RELB,NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimericp65-p50 complex appears to be most abundant one. The dimers bindat kappa-B sites in the DNA of their target genes and theindividual dimers have distinct preferences for different kappa-Bsites that they can bind with distinguishable affinity andspecificity. Different dimer combinations act as transcriptionalactivators or repressors, respectively. NF-kappa-B is controlledby various mechanisms of post-translational modification andsubcellular compartmentalization as well as by interactions withother cofactors or corepressors. NF-kappa-B complexes are held inthe cytoplasm in an inactive state complexed with members of theNF-kappa-B inhibitor (I-kappa-B) family. In a conventionalactivation pathway, I-kappa-B is phosphorylated by I-kappa-Bkinases (IKKs) in response to different activators, subsequentlydegraded thus liberating the active NF-kappa-B complex whichtranslocates to the nucleus. NF-kappa-B heterodimeric p65-p50 andRelB-p50 complexes are transcriptional activators. The NF-kappa-Bp50-p50 homodimer is a transcriptional repressor, but can act as atranscriptional activator when associated with BCL3. NFKB1 appearsto have dual functions such as cytoplasmic retention of attachedNF-kappa-B proteins by p105 and generation of p50 by acotranslational processing. The proteasome-mediated processensures the production of both p50 and p105 and preserves theirindependent function, although processing of NFKB1/p105 alsoappears to occur post-translationally. p50 binds to the kappa-Bconsensus sequence 5'-GGRNNYYCC-3', located in the enhancer regionof genes involved in immune response and acute phase reactions. Ina complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPKsignaling; active MAP3K8 is released by proteasome-dependentdegradation of NFKB1/p105. {ECO:0000269|PubMed:15485931}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for NFKB1_NFKB1 |
![]() (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for NFKB1_NFKB1 |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for NFKB1_NFKB1 |
![]() (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | NFKB1 | P19838 | DB01411 | Pranlukast | Nuclear factor NF-kappa-B p105 subunit | small molecule | approved|investigational |
Hgene | NFKB1 | P19838 | DB08814 | Triflusal | Nuclear factor NF-kappa-B p105 subunit | small molecule | approved|investigational |
Hgene | NFKB1 | P19838 | DB01041 | Thalidomide | Nuclear factor NF-kappa-B p105 subunit | small molecule | approved|investigational|withdrawn |
Tgene | NFKB1 | P19838 | DB01411 | Pranlukast | Nuclear factor NF-kappa-B p105 subunit | small molecule | approved|investigational |
Tgene | NFKB1 | P19838 | DB08814 | Triflusal | Nuclear factor NF-kappa-B p105 subunit | small molecule | approved|investigational |
Tgene | NFKB1 | P19838 | DB01041 | Thalidomide | Nuclear factor NF-kappa-B p105 subunit | small molecule | approved|investigational|withdrawn |
Top |
RelatedDiseases for NFKB1_NFKB1 |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | NFKB1 | C0001973 | Alcoholic Intoxication, Chronic | 4 | PSYGENET |
Hgene | NFKB1 | C0009375 | Colonic Neoplasms | 2 | CTD_human |
Hgene | NFKB1 | C0001418 | Adenocarcinoma | 1 | CTD_human |
Hgene | NFKB1 | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
Hgene | NFKB1 | C0007786 | Brain Ischemia | 1 | CTD_human |
Hgene | NFKB1 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
Hgene | NFKB1 | C0018843 | Heat Stroke | 1 | CTD_human |
Hgene | NFKB1 | C0020500 | Hyperoxaluria | 1 | CTD_human |
Hgene | NFKB1 | C0022661 | Kidney Failure, Chronic | 1 | CTD_human |
Hgene | NFKB1 | C0023892 | Biliary cirrhosis | 1 | CTD_human |
Hgene | NFKB1 | C0023895 | Liver diseases | 1 | CTD_human |
Hgene | NFKB1 | C0029927 | Ovarian Cysts | 1 | CTD_human |
Hgene | NFKB1 | C0525045 | Mood Disorders | 1 | PSYGENET |
Tgene | NFKB1 | C0001973 | Alcoholic Intoxication, Chronic | 4 | PSYGENET |
Tgene | NFKB1 | C0009375 | Colonic Neoplasms | 2 | CTD_human |
Tgene | NFKB1 | C0001418 | Adenocarcinoma | 1 | CTD_human |
Tgene | NFKB1 | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
Tgene | NFKB1 | C0007786 | Brain Ischemia | 1 | CTD_human |
Tgene | NFKB1 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
Tgene | NFKB1 | C0018843 | Heat Stroke | 1 | CTD_human |
Tgene | NFKB1 | C0020500 | Hyperoxaluria | 1 | CTD_human |
Tgene | NFKB1 | C0022661 | Kidney Failure, Chronic | 1 | CTD_human |
Tgene | NFKB1 | C0023892 | Biliary cirrhosis | 1 | CTD_human |
Tgene | NFKB1 | C0023895 | Liver diseases | 1 | CTD_human |
Tgene | NFKB1 | C0029927 | Ovarian Cysts | 1 | CTD_human |
Tgene | NFKB1 | C0525045 | Mood Disorders | 1 | PSYGENET |